Amgen’s Ian Thompson On Payer Shifts, Obesity Opportunity And The Future Of Blockbusters

Launches Have Longer Ramp-Up In High-Pressure Markets

 
• By Mandy Jackson

Scrip spoke with Amgen’s senior VP of US business operations about the impact of drug pricing and reimbursement pressures coming from government policy changes and commercial payers.

Close up of Amgen sign at its headquarters in Thousand Oaks, California, USA
Amgen's Enbrel is one of the first drugs under the IRA subject to Medicare negotiations • Source: Shutterstock

More from New Products

More from Scrip